Enter your email address below to receive the latest information about new products, promotions, and more.
DNA-In™ reagent is the newest generation transfection product developed by the lead members of the scientific team that invented the Lipofectamine® and Lipofectamine® 2000. A novel cationic transfection reagent that balances high transfection and expression levels with low toxicity, DNA-In™ works on a very broad range of adherent cells, including most passaged cell lines and many primary cells.
The development of DNA-In™ involved extensive validation testing in a range of primary and cultured cells. In head-to-head comparison studies, DNA-In™ consistently outperformed the * Lipofectamine® 2000 transfection reagent.
Cells were transfected with a plasmid, containing EmeraldGFP behind an EF1α promoter, with either DNA-In™ or Lipofectamine®2000, at several different lipid:DNA ratios and examined ~44 hours post-transfection. Representative images of the best conditions for each transfection reagent are shown.
DNA-In has a significantly lower cell toxicity compared to traditional transfection reagents such as Lipofectamine and Lipofectamine 2000. In the many cell lines tested, DNA-In shows a broad range of effective dosage while maintaining minimal cell toxicity. This low cell toxicity allows a larger dosage and time window for optimized transfection results.
The following charts show side-by-side comparisons of DNA-In and Lipofectamine 2000 (LF2K) in commonly used cell lines and primary cells:
In 293 cells, DNA-In maintains high cell viability throughout the tested dosage range, while LF2K has a significant cell toxicity issue when used in dosages over 3 ul.
In A549 cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.
In human fibroblast cells, DNA-In has a significantly higher transfection efficiency and a lower cell toxicity while LF2K performs poorly in both parameters.